Genmab A/S (NASDAQ:GMAB) Stock Price Target Lowered at Morgan Stanley

Genmab A/S (NASDAQ:GMAB) had its price objective decreased by stock analysts at Morgan Stanley from $57.00 to $56.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley‘s price objective suggests a potential upside of 9.71% from the stock’s previous close.

A number of other research firms have also recently weighed in on GMAB. HC Wainwright upped their price target on shares of Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Truist Financial reiterated a “buy” rating and issued a $67.00 price objective (up from $45.00) on shares of Genmab A/S in a research note on Thursday, October 29th. JPMorgan Chase & Co. upgraded shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday, October 26th. New Street Research set a $43.00 price objective on shares of Genmab A/S in a report on Wednesday, July 22nd. Finally, TD Cowen upped their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $53.50.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded down $0.70 during trading on Friday, reaching $51.04. The company’s stock had a trading volume of 1,762,876 shares, compared to its average volume of 2,565,287. The company has a quick ratio of 2.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.74. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $59.97. The company has a market capitalization of $31.85 billion, a P/E ratio of 43.64, a price-to-earnings-growth ratio of 2.17 and a beta of 0.73. The business has a 50 day moving average price of $40.81 and a 200-day moving average price of $31.52.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.20. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.20 billion. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.28 EPS for the current year.

Institutional Trading of Genmab A/S

Large investors have recently bought and sold shares of the company. First Trust Advisors LP increased its position in shares of Genmab A/S by 84.3% in the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after buying an additional 1,126,069 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after buying an additional 921,700 shares in the last quarter. HighVista Strategies LLC purchased a new stake in shares of Genmab A/S in the 3rd quarter worth about $8,066,000. Aberdeen Group plc purchased a new stake in shares of Genmab A/S in the 3rd quarter worth about $3,948,000. Finally, Pictet Asset Management Holding SA grew its stake in Genmab A/S by 8.0% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,150,854 shares of the company’s stock valued at $41,044,000 after acquiring an additional 84,927 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.